KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) EBIT Margin (2017 - 2025)

Historic EBIT Margin for Aquestive Therapeutics (AQST) over the last 9 years, with Q3 2025 value amounting to 89.63%.

  • Aquestive Therapeutics' EBIT Margin fell 284100.0% to 89.63% in Q3 2025 from the same period last year, while for Sep 2025 it was 424.07%, marking a year-over-year increase of 4599000.0%. This contributed to the annual value of 3052.68% for FY2024, which is 30228200.0% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported EBIT Margin of 89.63% as of Q3 2025, which was down 284100.0% from 113.65% recorded in Q2 2025.
  • Aquestive Therapeutics' EBIT Margin's 5-year high stood at 30.39% during Q4 2024, with a 5-year trough of 325.85% in Q2 2021.
  • Its 5-year average for EBIT Margin is 87.65%, with a median of 77.23% in 2022.
  • Over the last 5 years, Aquestive Therapeutics' EBIT Margin had its largest YoY gain of 2845600bps in 2021, and its largest YoY loss of -4048500bps in 2021.
  • Quarter analysis of 5 years shows Aquestive Therapeutics' EBIT Margin stood at 105.33% in 2021, then rose by 5bps to 100.29% in 2022, then skyrocketed by 70bps to 29.62% in 2023, then surged by 203bps to 30.39% in 2024, then plummeted by -395bps to 89.63% in 2025.
  • Its EBIT Margin was 89.63% in Q3 2025, compared to 113.65% in Q2 2025 and 222.08% in Q1 2025.